Group 1: Sales and Marketing Strategy - The main sales model for Yong'an Kangjian is primarily online, with products sold through platforms like Tmall, JD.com, Taobao, and Amazon [2][3] - The company has established a partnership with Jamieson, a leading Canadian health food brand, acquiring exclusive agency rights in China [3][4] - The company is actively enhancing its cross-border e-commerce channels to expand the market for Jamieson products domestically [3][4] Group 2: Production Capacity and Pricing - The current production capacity for taurine is 34,000 tons, with a utilization rate that is linked to market prices [4][5] - The price of taurine has seen a slight recovery, influenced by raw material costs [4][5] - The fluctuation in the price of ethylene oxide has a certain impact on taurine pricing, with approximately one-third of ethylene oxide being used for in-house production [4][5] Group 3: Environmental and Regulatory Compliance - The company is increasing investments in environmental protection, with stable operation of waste treatment facilities [5] - Two environmental penalty issues are being addressed, including the relocation of a 10,000 tons/year taurine project, which is now ready for acceptance [5] - The government has initiated relocation work for residents affected by the expansion of a 40,000 tons/year ethylene oxide project, with property evaluations currently underway [5] Group 4: Employee Incentives and Corporate Governance - After going public, the company has not implemented new equity incentive plans, relying instead on performance bonuses linked to company goals to motivate employees [5]

证券代码：永安药业 证券简称：002365 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2015-02 | --- | --- | --- | --- | |-------------------------|--------------------------------|--------------------------------------------------|--------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 □媒体采访 | | | 投资者关系 | □ | 业绩说明会 □新闻发布会 □路演活动 | | | 活动类别 | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 天津尚道投资有限公司：张伟生 | | | | 时间 | 2015 年 5 月 11 日 | | | | 地点 | 公司会议室 | | | | 公司接待人员 | 公司董秘：吴晓波 | | | | 姓名 | 证券事务代表：邓永红 | | | | 投资者关系 | ...

证券代码：永安药业 证券简称：002365 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2015-05 | --- | --- | --- | --- | --- | |-------------------------|----------------------------------|-------|---------------------------------------------------------------------------------------|----------------------------------------------------------| | 投资者关系 | √ \n□ | | 特定对象调研 □分析师会议 □媒体采访 \n业绩说明会 □新闻发布会 □路演活动 | | | 活动类别 | □ | | 现场参观 □其他 （请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 华夏基金：王泽实 | | | | | 时间 | 2015 年 12 月 2 日 | | | | | 地点 | 公司会议室 | | | | | 公司接待人员 姓名 ...

Group 1: Company Production and Operations - The company currently has a production capacity of 34,000 tons for taurine, with an annual output of 24,000 tons [2] - The production capacity for ethylene oxide is 40,000 tons, but the output was low last year due to the project being in trial operation [2] - Approximately two-thirds of the ethylene oxide produced is sold overseas [3] Group 2: Cost Advantages and Market Position - The cost advantages of taurine production are primarily due to technological, scale, and raw material procurement advantages [3] - The company is actively increasing research and development efforts for taurine downstream products to meet diverse consumer needs [3] Group 3: Subsidiary Operations and Product Sales - The subsidiary, Kangjian Pharmaceutical, is currently operating normally with steady growth in online sales and improving offline channels [4] - The company is selling foreign health products such as natto kinase capsules and deep-sea fish oil soft capsules, and is working to introduce more foreign products [4] Group 4: Future Development Plans - The global demand for taurine is continuously growing, with significant development potential in the domestic market [4] - The company plans to enhance its marketing team and brand promotion efforts in 2015 to increase market share [4] - There are no known plans for major shareholders to reduce their holdings, as such decisions are personal and will be disclosed if the company is informed [5]

证券代码：永安药业 证券简称：002365 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2015-01 | --- | --- | --- | --- | |-------------------------|------------------------------------------------------|--------------------------------------------------|----------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 □媒体采访 | | | 投资者关系 | □ | 业绩说明会 □新闻发布会 □路演活动 | | | 活动类别 | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 北京壹人资本管理有限公司：任为重 | | | | 时间 | 2015 年 4 月 27 日 | | | | 地点 | 公司会议室 | | | | 公司接待人员 | 质量技术负责人：赵小华、李少波，证券事务代表 ...

Group 1: Company Overview - Yong'an Pharmaceutical is the largest taurine production base globally, holding over 50% of the market share [2] - The company’s products are primarily exported, with over 80% of taurine products being sold internationally [2] Group 2: Product Characteristics and Applications - Taurine is an amino acid with various physiological functions, crucial for infant brain development and nutrient absorption [3] - It is widely used in functional beverages, pharmaceutical raw materials, pet food, and as an important ingredient in many health products [3] Group 3: Market Position and Strategy - Despite a high market share in taurine, the company does not possess absolute pricing power due to intense competition [4] - The company aims to maintain its leading position in the taurine industry and expand into the health sector, targeting over 50% market share [4] Group 4: Environmental and Regulatory Compliance - The company has resolved its major environmental issues and recently received approval for an annual production capacity of 40,000 tons of ethylene oxide [5] Group 5: Product Development and Sales Channels - Yong'an Health currently has 3 health product approvals and is working on 7 additional products, with plans for more submissions in 2016 [5] - Online sales channels include major platforms like Tmall, JD.com, and Amazon, while offline channels consist of supermarkets and direct sales [5] Group 6: Brand Strategy and Market Influence - The company has chosen to represent Jamieson, a leading Canadian health brand, to enhance its own brand growth and align with its strategic shift towards the health industry [6] - The sales of Jamieson products are primarily conducted through cross-border e-commerce, influenced by current health product policies [6] Group 7: Investment in Health and Elderly Care - In July 2015, the company established Wuhan Yaan Investment Management Co., Ltd. to manage investments in the health and elderly care sectors [6] - The investment aims to accelerate development, improve capital efficiency, and cultivate new profit growth points [6] Group 8: Future Investment Plans - Currently, Wuhan Yaan Investment Management Co., Ltd. is exploring potential projects in health management and elderly care, with no specific investments confirmed yet [7]

Group 1: Market and Product Insights - Taurine prices are currently low, with competitors including Huanggang Fuchi Pharmaceutical, Jiangyin Huachang Food Additives, and Jiangsu Yuanyang Pharmaceutical, with a total production capacity of 34,000 tons [2][3] - The future market space for taurine may see slight growth, supported by the company's strong brand and market position [3] - The company has received approval for taurine effervescent tablets, with ongoing preparations for production and market promotion [4] Group 2: Financial Performance - In the third quarter, the company's operating revenue and profit both declined year-on-year, primarily due to the suspension of the ethylene oxide project, which resulted in no sales revenue [5] - The net profit attributable to shareholders for 2015 is projected to decline by 10% to 60% compared to the previous year [5] - The company is actively expanding its market channels and increasing product investment and promotion, particularly for its subsidiary, Yong'an Health [5][6] Group 3: Investment and Strategic Planning - The company has established a new investment firm, Wuhan Yaan Investment Management Co., Ltd., to manage investments in the health and elderly care sectors [4] - The board has approved a share repurchase plan, with ongoing disclosures regarding the progress of the repurchase [6] - The long-term strategic focus is on expanding into the health industry, with plans to explore new markets and cultivate new profit growth points [6]

证券代码：永安药业 证券简称：002365 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2016-03 | --- | --- | --- | --- | |-----------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------| | 投资者关系 \n活动类别 | √ \n□ \n□ | 特定对象调研 □分析师会议 □媒体采访 \n业绩说明会 □新闻发布会 □路演活动 \n现场参观 □其他 （请文字说明其他活动内容） | | | 参与单位名称 | | 华泰证券：杨烨辉；华商基金：彭欣杨； | | | 及人员姓名 | | 华安基金：袁银泉；博时基金：葛 晨。 | ...

证券代码：永安药业 证券简称：002365 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2016-02 | --- | --- | --- | --- | --- | |-------------------------|--------------------------------|---------------------------------------------------------------------------------------|-------|----------------------------------------------------------------| | 投资者关系 | √ \n□ | 特定对象调研 □分析师会议 □媒体采访 \n业绩说明会 □新闻发布会 □路演活动 | | | | 活动类别 | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | | 参与单位名称 | 安信证券股份有限公司：周 烽 | | | | | 及人员姓名 | 天津尚道投资有限公司：张伟生 | | | | | 时间 | 2016 年 1 月 18 日 | | ...